The global market for Antibody–Drug Conjugate Development Solutions was valued at US$ 113 million in the year 2024 and is projected to reach a revised size of US$ 165 million by 2031, growing at a CAGR of 5.6% during the forecast period.

Antibody–Drug Conjugate Development Solutions Market

Antibody–Drug Conjugate (ADC) development solutions refer to the strategies, technologies, and services used in the creation and optimization of ADCs, which are a class of targeted cancer therapies. ADCs are designed to deliver potent cytotoxic (cell-killing) drugs directly to cancer cells while minimizing damage to healthy tissue.

North American market for Antibody–Drug Conjugate Development Solutions is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Asia-Pacific market for Antibody–Drug Conjugate Development Solutions is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The global market for Antibody–Drug Conjugate Development Solutions in Oncology is estimated to increase from $ million in 2024 to $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The major global companies of Antibody–Drug Conjugate Development Solutions include Sino Biological, ProteoGenix, Labcorp, Promega Corporation, Charles River Laboratories, Sterling Pharma Solutions Limited, Revvity, WuXi Biologics, Abzena, Samsung Biologics, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

This report aims to provide a comprehensive presentation of the global market for Antibody–Drug Conjugate Development Solutions, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Antibody–Drug Conjugate Development Solutions.

The Antibody–Drug Conjugate Development Solutions market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Antibody–Drug Conjugate Development Solutions market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Antibody–Drug Conjugate Development Solutions companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Market Segmentation

Scope of Antibody–Drug Conjugate Development Solutions Market Report

Report Metric	Details
Report Name	Antibody–Drug Conjugate Development Solutions Market
Accounted market size in year	US$ 113 million
Forecasted market size in 2031	US$ 165 million
CAGR	5.6%
Base Year	year
Forecasted years	2025 - 2031
Segment by Type	Conjugation Process Development Antibody Selection and Optimization Other
Segment by Application	Oncology Personalized Medicine Combination Therapy
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Sino Biological, ProteoGenix, Labcorp, Promega Corporation, Charles River Laboratories, Sterling Pharma Solutions Limited, Revvity, WuXi Biologics, Abzena, Samsung Biologics
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Antibody–Drug Conjugate Development Solutions company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

FAQ for this report

How fast is Antibody–Drug Conjugate Development Solutions Market growing?

Ans: The Antibody–Drug Conjugate Development Solutions Market witnessing a CAGR of 5.6% during the forecast period 2025-2031.

What is the Antibody–Drug Conjugate Development Solutions Market size in 2031?

Ans: The Antibody–Drug Conjugate Development Solutions Market size in 2031 will be US$ 165 million.

Who are the main players in the Antibody–Drug Conjugate Development Solutions Market report?

Ans: The main players in the Antibody–Drug Conjugate Development Solutions Market are Sino Biological, ProteoGenix, Labcorp, Promega Corporation, Charles River Laboratories, Sterling Pharma Solutions Limited, Revvity, WuXi Biologics, Abzena, Samsung Biologics

What are the Application segmentation covered in the Antibody–Drug Conjugate Development Solutions Market report?

Ans: The Applications covered in the Antibody–Drug Conjugate Development Solutions Market report are Oncology, Personalized Medicine, Combination Therapy

What are the Type segmentation covered in the Antibody–Drug Conjugate Development Solutions Market report?

Ans: The Types covered in the Antibody–Drug Conjugate Development Solutions Market report are Conjugation Process Development, Antibody Selection and Optimization, Other

1 Report Overview

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Antibody–Drug Conjugate Development Solutions Market Size Growth Rate by Type: 2020 VS 2024 VS 2031

1.2.2 Conjugation Process Development

1.2.3 Antibody Selection and Optimization

1.2.4 Other

1.3 Market by Application

1.3.1 Global Antibody–Drug Conjugate Development Solutions Market Growth by Application: 2020 VS 2024 VS 2031

1.3.2 Oncology

1.3.3 Personalized Medicine

1.3.4 Combination Therapy

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Global Growth Trends

2.1 Global Antibody–Drug Conjugate Development Solutions Market Perspective (2020-2031)

2.2 Global Antibody–Drug Conjugate Development Solutions Growth Trends by Region

2.2.1 Global Antibody–Drug Conjugate Development Solutions Market Size by Region: 2020 VS 2024 VS 2031

2.2.2 Antibody–Drug Conjugate Development Solutions Historic Market Size by Region (2020-2025)

2.2.3 Antibody–Drug Conjugate Development Solutions Forecasted Market Size by Region (2026-2031)

2.3 Antibody–Drug Conjugate Development Solutions Market Dynamics

2.3.1 Antibody–Drug Conjugate Development Solutions Industry Trends

2.3.2 Antibody–Drug Conjugate Development Solutions Market Drivers

2.3.3 Antibody–Drug Conjugate Development Solutions Market Challenges

2.3.4 Antibody–Drug Conjugate Development Solutions Market Restraints

3 Competition Landscape by Key Players

3.1 Global Top Antibody–Drug Conjugate Development Solutions Players by Revenue

3.1.1 Global Top Antibody–Drug Conjugate Development Solutions Players by Revenue (2020-2025)

3.1.2 Global Antibody–Drug Conjugate Development Solutions Revenue Market Share by Players (2020-2025)

3.2 Global Top Antibody–Drug Conjugate Development Solutions Players by Company Type and Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Global Key Players Ranking by Antibody–Drug Conjugate Development Solutions Revenue

3.4 Global Antibody–Drug Conjugate Development Solutions Market Concentration Ratio

3.4.1 Global Antibody–Drug Conjugate Development Solutions Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Antibody–Drug Conjugate Development Solutions Revenue in 2024

3.5 Global Key Players of Antibody–Drug Conjugate Development Solutions Head office and Area Served

3.6 Global Key Players of Antibody–Drug Conjugate Development Solutions, Product and Application

3.7 Global Key Players of Antibody–Drug Conjugate Development Solutions, Date of Enter into This Industry

3.8 Mergers & Acquisitions, Expansion Plans

4 Antibody–Drug Conjugate Development Solutions Breakdown Data by Type

4.1 Global Antibody–Drug Conjugate Development Solutions Historic Market Size by Type (2020-2025)

4.2 Global Antibody–Drug Conjugate Development Solutions Forecasted Market Size by Type (2026-2031)

5 Antibody–Drug Conjugate Development Solutions Breakdown Data by Application

5.1 Global Antibody–Drug Conjugate Development Solutions Historic Market Size by Application (2020-2025)

5.2 Global Antibody–Drug Conjugate Development Solutions Forecasted Market Size by Application (2026-2031)

6 North America

6.1 North America Antibody–Drug Conjugate Development Solutions Market Size (2020-2031)

6.2 North America Antibody–Drug Conjugate Development Solutions Market Growth Rate by Country: 2020 VS 2024 VS 2031

6.3 North America Antibody–Drug Conjugate Development Solutions Market Size by Country (2020-2025)

6.4 North America Antibody–Drug Conjugate Development Solutions Market Size by Country (2026-2031)

6.5 United States

6.6 Canada

7 Europe

7.1 Europe Antibody–Drug Conjugate Development Solutions Market Size (2020-2031)

7.2 Europe Antibody–Drug Conjugate Development Solutions Market Growth Rate by Country: 2020 VS 2024 VS 2031

7.3 Europe Antibody–Drug Conjugate Development Solutions Market Size by Country (2020-2025)

7.4 Europe Antibody–Drug Conjugate Development Solutions Market Size by Country (2026-2031)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Nordic Countries

8 Asia-Pacific

8.1 Asia-Pacific Antibody–Drug Conjugate Development Solutions Market Size (2020-2031)

8.2 Asia-Pacific Antibody–Drug Conjugate Development Solutions Market Growth Rate by Region: 2020 VS 2024 VS 2031

8.3 Asia-Pacific Antibody–Drug Conjugate Development Solutions Market Size by Region (2020-2025)

8.4 Asia-Pacific Antibody–Drug Conjugate Development Solutions Market Size by Region (2026-2031)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia

9 Latin America

9.1 Latin America Antibody–Drug Conjugate Development Solutions Market Size (2020-2031)

9.2 Latin America Antibody–Drug Conjugate Development Solutions Market Growth Rate by Country: 2020 VS 2024 VS 2031

9.3 Latin America Antibody–Drug Conjugate Development Solutions Market Size by Country (2020-2025)

9.4 Latin America Antibody–Drug Conjugate Development Solutions Market Size by Country (2026-2031)

9.5 Mexico

9.6 Brazil

10 Middle East & Africa

10.1 Middle East & Africa Antibody–Drug Conjugate Development Solutions Market Size (2020-2031)

10.2 Middle East & Africa Antibody–Drug Conjugate Development Solutions Market Growth Rate by Country: 2020 VS 2024 VS 2031

10.3 Middle East & Africa Antibody–Drug Conjugate Development Solutions Market Size by Country (2020-2025)

10.4 Middle East & Africa Antibody–Drug Conjugate Development Solutions Market Size by Country (2026-2031)

10.5 Turkey

10.6 Saudi Arabia

10.7 UAE

11 Key Players Profiles

11.1 Sino Biological

11.1.1 Sino Biological Company Details

11.1.2 Sino Biological Business Overview

11.1.3 Sino Biological Antibody–Drug Conjugate Development Solutions Introduction

11.1.4 Sino Biological Revenue in Antibody–Drug Conjugate Development Solutions Business (2020-2025)

11.1.5 Sino Biological Recent Development

11.2 ProteoGenix

11.2.1 ProteoGenix Company Details

11.2.2 ProteoGenix Business Overview

11.2.3 ProteoGenix Antibody–Drug Conjugate Development Solutions Introduction

11.2.4 ProteoGenix Revenue in Antibody–Drug Conjugate Development Solutions Business (2020-2025)

11.2.5 ProteoGenix Recent Development

11.3 Labcorp

11.3.1 Labcorp Company Details

11.3.2 Labcorp Business Overview

11.3.3 Labcorp Antibody–Drug Conjugate Development Solutions Introduction

11.3.4 Labcorp Revenue in Antibody–Drug Conjugate Development Solutions Business (2020-2025)

11.3.5 Labcorp Recent Development

11.4 Promega Corporation

11.4.1 Promega Corporation Company Details

11.4.2 Promega Corporation Business Overview

11.4.3 Promega Corporation Antibody–Drug Conjugate Development Solutions Introduction

11.4.4 Promega Corporation Revenue in Antibody–Drug Conjugate Development Solutions Business (2020-2025)

11.4.5 Promega Corporation Recent Development

11.5 Charles River Laboratories

11.5.1 Charles River Laboratories Company Details

11.5.2 Charles River Laboratories Business Overview

11.5.3 Charles River Laboratories Antibody–Drug Conjugate Development Solutions Introduction

11.5.4 Charles River Laboratories Revenue in Antibody–Drug Conjugate Development Solutions Business (2020-2025)

11.5.5 Charles River Laboratories Recent Development

11.6 Sterling Pharma Solutions Limited

11.6.1 Sterling Pharma Solutions Limited Company Details

11.6.2 Sterling Pharma Solutions Limited Business Overview

11.6.3 Sterling Pharma Solutions Limited Antibody–Drug Conjugate Development Solutions Introduction

11.6.4 Sterling Pharma Solutions Limited Revenue in Antibody–Drug Conjugate Development Solutions Business (2020-2025)

11.6.5 Sterling Pharma Solutions Limited Recent Development

11.7 Revvity

11.7.1 Revvity Company Details

11.7.2 Revvity Business Overview

11.7.3 Revvity Antibody–Drug Conjugate Development Solutions Introduction

11.7.4 Revvity Revenue in Antibody–Drug Conjugate Development Solutions Business (2020-2025)

11.7.5 Revvity Recent Development

11.8 WuXi Biologics

11.8.1 WuXi Biologics Company Details

11.8.2 WuXi Biologics Business Overview

11.8.3 WuXi Biologics Antibody–Drug Conjugate Development Solutions Introduction

11.8.4 WuXi Biologics Revenue in Antibody–Drug Conjugate Development Solutions Business (2020-2025)

11.8.5 WuXi Biologics Recent Development

11.9 Abzena

11.9.1 Abzena Company Details

11.9.2 Abzena Business Overview

11.9.3 Abzena Antibody–Drug Conjugate Development Solutions Introduction

11.9.4 Abzena Revenue in Antibody–Drug Conjugate Development Solutions Business (2020-2025)

11.9.5 Abzena Recent Development

11.10 Samsung Biologics

11.10.1 Samsung Biologics Company Details

11.10.2 Samsung Biologics Business Overview

11.10.3 Samsung Biologics Antibody–Drug Conjugate Development Solutions Introduction

11.10.4 Samsung Biologics Revenue in Antibody–Drug Conjugate Development Solutions Business (2020-2025)

11.10.5 Samsung Biologics Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.1.1 Research Programs/Design

13.1.1.2 Market Size Estimation

13.1.1.3 Market Breakdown and Data Triangulation

13.1.2 Data Source

13.1.2.1 Secondary Sources

13.1.2.2 Primary Sources

13.2 Author Details

13.3 Disclaimer

FEATURED COMPANIES

Charles River Laboratories

Sterling Pharma Solutions Limited

List of Tables

Table 1. Global Antibody–Drug Conjugate Development Solutions Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031

Table 2. Key Players of Conjugation Process Development

Table 3. Key Players of Antibody Selection and Optimization

Table 4. Key Players of Other

Table 5. Global Antibody–Drug Conjugate Development Solutions Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031

Table 6. Global Antibody–Drug Conjugate Development Solutions Market Size by Region (US$ Million): 2020 VS 2024 VS 2031

Table 7. Global Antibody–Drug Conjugate Development Solutions Market Size by Region (2020-2025) & (US$ Million)

Table 8. Global Antibody–Drug Conjugate Development Solutions Market Share by Region (2020-2025)

Table 9. Global Antibody–Drug Conjugate Development Solutions Forecasted Market Size by Region (2026-2031) & (US$ Million)

Table 10. Global Antibody–Drug Conjugate Development Solutions Market Share by Region (2026-2031)

Table 11. Antibody–Drug Conjugate Development Solutions Market Trends

Table 12. Antibody–Drug Conjugate Development Solutions Market Drivers

Table 13. Antibody–Drug Conjugate Development Solutions Market Challenges

Table 14. Antibody–Drug Conjugate Development Solutions Market Restraints

Table 15. Global Antibody–Drug Conjugate Development Solutions Revenue by Players (2020-2025) & (US$ Million)

Table 16. Global Antibody–Drug Conjugate Development Solutions Market Share by Players (2020-2025)

Table 17. Global Top Antibody–Drug Conjugate Development Solutions Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Antibody–Drug Conjugate Development Solutions as of 2024)

Table 18. Ranking of Global Top Antibody–Drug Conjugate Development Solutions Companies by Revenue (US$ Million) in 2024

Table 19. Global 5 Largest Players Market Share by Antibody–Drug Conjugate Development Solutions Revenue (CR5 and HHI) & (2020-2025)

Table 20. Global Key Players of Antibody–Drug Conjugate Development Solutions, Headquarters and Area Served

Table 21. Global Key Players of Antibody–Drug Conjugate Development Solutions, Product and Application

Table 22. Global Key Players of Antibody–Drug Conjugate Development Solutions, Date of Enter into This Industry

Table 23. Mergers & Acquisitions, Expansion Plans

Table 24. Global Antibody–Drug Conjugate Development Solutions Market Size by Type (2020-2025) & (US$ Million)

Table 25. Global Antibody–Drug Conjugate Development Solutions Revenue Market Share by Type (2020-2025)

Table 26. Global Antibody–Drug Conjugate Development Solutions Forecasted Market Size by Type (2026-2031) & (US$ Million)

Table 27. Global Antibody–Drug Conjugate Development Solutions Revenue Market Share by Type (2026-2031)

Table 28. Global Antibody–Drug Conjugate Development Solutions Market Size by Application (2020-2025) & (US$ Million)

Table 29. Global Antibody–Drug Conjugate Development Solutions Revenue Market Share by Application (2020-2025)

Table 30. Global Antibody–Drug Conjugate Development Solutions Forecasted Market Size by Application (2026-2031) & (US$ Million)

Table 31. Global Antibody–Drug Conjugate Development Solutions Revenue Market Share by Application (2026-2031)

Table 32. North America Antibody–Drug Conjugate Development Solutions Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 33. North America Antibody–Drug Conjugate Development Solutions Market Size by Country (2020-2025) & (US$ Million)

Table 34. North America Antibody–Drug Conjugate Development Solutions Market Size by Country (2026-2031) & (US$ Million)

Table 35. Europe Antibody–Drug Conjugate Development Solutions Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 36. Europe Antibody–Drug Conjugate Development Solutions Market Size by Country (2020-2025) & (US$ Million)

Table 37. Europe Antibody–Drug Conjugate Development Solutions Market Size by Country (2026-2031) & (US$ Million)

Table 38. Asia-Pacific Antibody–Drug Conjugate Development Solutions Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031

Table 39. Asia-Pacific Antibody–Drug Conjugate Development Solutions Market Size by Region (2020-2025) & (US$ Million)

Table 40. Asia-Pacific Antibody–Drug Conjugate Development Solutions Market Size by Region (2026-2031) & (US$ Million)

Table 41. Latin America Antibody–Drug Conjugate Development Solutions Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 42. Latin America Antibody–Drug Conjugate Development Solutions Market Size by Country (2020-2025) & (US$ Million)

Table 43. Latin America Antibody–Drug Conjugate Development Solutions Market Size by Country (2026-2031) & (US$ Million)

Table 44. Middle East & Africa Antibody–Drug Conjugate Development Solutions Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 45. Middle East & Africa Antibody–Drug Conjugate Development Solutions Market Size by Country (2020-2025) & (US$ Million)

Table 46. Middle East & Africa Antibody–Drug Conjugate Development Solutions Market Size by Country (2026-2031) & (US$ Million)

Table 47. Sino Biological Company Details

Table 48. Sino Biological Business Overview

Table 49. Sino Biological Antibody–Drug Conjugate Development Solutions Product

Table 50. Sino Biological Revenue in Antibody–Drug Conjugate Development Solutions Business (2020-2025) & (US$ Million)

Table 51. Sino Biological Recent Development

Table 52. ProteoGenix Company Details

Table 53. ProteoGenix Business Overview

Table 54. ProteoGenix Antibody–Drug Conjugate Development Solutions Product

Table 55. ProteoGenix Revenue in Antibody–Drug Conjugate Development Solutions Business (2020-2025) & (US$ Million)

Table 56. ProteoGenix Recent Development

Table 57. Labcorp Company Details

Table 58. Labcorp Business Overview

Table 59. Labcorp Antibody–Drug Conjugate Development Solutions Product

Table 60. Labcorp Revenue in Antibody–Drug Conjugate Development Solutions Business (2020-2025) & (US$ Million)

Table 61. Labcorp Recent Development

Table 62. Promega Corporation Company Details

Table 63. Promega Corporation Business Overview

Table 64. Promega Corporation Antibody–Drug Conjugate Development Solutions Product

Table 65. Promega Corporation Revenue in Antibody–Drug Conjugate Development Solutions Business (2020-2025) & (US$ Million)

Table 66. Promega Corporation Recent Development

Table 67. Charles River Laboratories Company Details

Table 68. Charles River Laboratories Business Overview

Table 69. Charles River Laboratories Antibody–Drug Conjugate Development Solutions Product

Table 70. Charles River Laboratories Revenue in Antibody–Drug Conjugate Development Solutions Business (2020-2025) & (US$ Million)

Table 71. Charles River Laboratories Recent Development

Table 72. Sterling Pharma Solutions Limited Company Details

Table 73. Sterling Pharma Solutions Limited Business Overview

Table 74. Sterling Pharma Solutions Limited Antibody–Drug Conjugate Development Solutions Product

Table 75. Sterling Pharma Solutions Limited Revenue in Antibody–Drug Conjugate Development Solutions Business (2020-2025) & (US$ Million)

Table 76. Sterling Pharma Solutions Limited Recent Development

Table 77. Revvity Company Details

Table 78. Revvity Business Overview

Table 79. Revvity Antibody–Drug Conjugate Development Solutions Product

Table 80. Revvity Revenue in Antibody–Drug Conjugate Development Solutions Business (2020-2025) & (US$ Million)

Table 81. Revvity Recent Development

Table 82. WuXi Biologics Company Details

Table 83. WuXi Biologics Business Overview

Table 84. WuXi Biologics Antibody–Drug Conjugate Development Solutions Product

Table 85. WuXi Biologics Revenue in Antibody–Drug Conjugate Development Solutions Business (2020-2025) & (US$ Million)

Table 86. WuXi Biologics Recent Development

Table 87. Abzena Company Details

Table 88. Abzena Business Overview

Table 89. Abzena Antibody–Drug Conjugate Development Solutions Product

Table 90. Abzena Revenue in Antibody–Drug Conjugate Development Solutions Business (2020-2025) & (US$ Million)

Table 91. Abzena Recent Development

Table 92. Samsung Biologics Company Details

Table 93. Samsung Biologics Business Overview

Table 94. Samsung Biologics Antibody–Drug Conjugate Development Solutions Product

Table 95. Samsung Biologics Revenue in Antibody–Drug Conjugate Development Solutions Business (2020-2025) & (US$ Million)

Table 96. Samsung Biologics Recent Development

Table 97. Research Programs/Design for This Report

Table 98. Key Data Information from Secondary Sources

Table 99. Key Data Information from Primary Sources

Table 100. Authors List of This Report

List of Figures

Figure 1. Antibody–Drug Conjugate Development Solutions Picture

Figure 2. Global Antibody–Drug Conjugate Development Solutions Market Size Comparison by Type (2020-2031) & (US$ Million)

Figure 3. Global Antibody–Drug Conjugate Development Solutions Market Share by Type: 2024 VS 2031

Figure 4. Conjugation Process Development Features

Figure 5. Antibody Selection and Optimization Features

Figure 6. Other Features

Figure 7. Global Antibody–Drug Conjugate Development Solutions Market Size by Application (2020-2031) & (US$ Million)

Figure 8. Global Antibody–Drug Conjugate Development Solutions Market Share by Application: 2024 VS 2031

Figure 9. Oncology Case Studies

Figure 10. Personalized Medicine Case Studies

Figure 11. Combination Therapy Case Studies

Figure 12. Antibody–Drug Conjugate Development Solutions Report Years Considered

Figure 13. Global Antibody–Drug Conjugate Development Solutions Market Size (US$ Million), Year-over-Year: 2020-2031

Figure 14. Global Antibody–Drug Conjugate Development Solutions Market Size, (US$ Million), 2020 VS 2024 VS 2031

Figure 15. Global Antibody–Drug Conjugate Development Solutions Market Share by Region: 2024 VS 2031

Figure 16. Global Antibody–Drug Conjugate Development Solutions Market Share by Players in 2024

Figure 17. Global Antibody–Drug Conjugate Development Solutions Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

Figure 18. The Top 10 and 5 Players Market Share by Antibody–Drug Conjugate Development Solutions Revenue in 2024

Figure 19. North America Antibody–Drug Conjugate Development Solutions Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 20. North America Antibody–Drug Conjugate Development Solutions Market Share by Country (2020-2031)

Figure 21. United States Antibody–Drug Conjugate Development Solutions Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 22. Canada Antibody–Drug Conjugate Development Solutions Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 23. Europe Antibody–Drug Conjugate Development Solutions Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 24. Europe Antibody–Drug Conjugate Development Solutions Market Share by Country (2020-2031)

Figure 25. Germany Antibody–Drug Conjugate Development Solutions Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 26. France Antibody–Drug Conjugate Development Solutions Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 27. U.K. Antibody–Drug Conjugate Development Solutions Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 28. Italy Antibody–Drug Conjugate Development Solutions Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 29. Russia Antibody–Drug Conjugate Development Solutions Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 30. Nordic Countries Antibody–Drug Conjugate Development Solutions Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 31. Asia-Pacific Antibody–Drug Conjugate Development Solutions Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 32. Asia-Pacific Antibody–Drug Conjugate Development Solutions Market Share by Region (2020-2031)

Figure 33. China Antibody–Drug Conjugate Development Solutions Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 34. Japan Antibody–Drug Conjugate Development Solutions Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 35. South Korea Antibody–Drug Conjugate Development Solutions Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 36. Southeast Asia Antibody–Drug Conjugate Development Solutions Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 37. India Antibody–Drug Conjugate Development Solutions Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 38. Australia Antibody–Drug Conjugate Development Solutions Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 39. Latin America Antibody–Drug Conjugate Development Solutions Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 40. Latin America Antibody–Drug Conjugate Development Solutions Market Share by Country (2020-2031)

Figure 41. Mexico Antibody–Drug Conjugate Development Solutions Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 42. Brazil Antibody–Drug Conjugate Development Solutions Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 43. Middle East & Africa Antibody–Drug Conjugate Development Solutions Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 44. Middle East & Africa Antibody–Drug Conjugate Development Solutions Market Share by Country (2020-2031)

Figure 45. Turkey Antibody–Drug Conjugate Development Solutions Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 46. Saudi Arabia Antibody–Drug Conjugate Development Solutions Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 47. UAE Antibody–Drug Conjugate Development Solutions Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 48. Sino Biological Revenue Growth Rate in Antibody–Drug Conjugate Development Solutions Business (2020-2025)

Figure 49. ProteoGenix Revenue Growth Rate in Antibody–Drug Conjugate Development Solutions Business (2020-2025)

Figure 50. Labcorp Revenue Growth Rate in Antibody–Drug Conjugate Development Solutions Business (2020-2025)

Figure 51. Promega Corporation Revenue Growth Rate in Antibody–Drug Conjugate Development Solutions Business (2020-2025)

Figure 52. Charles River Laboratories Revenue Growth Rate in Antibody–Drug Conjugate Development Solutions Business (2020-2025)

Figure 53. Sterling Pharma Solutions Limited Revenue Growth Rate in Antibody–Drug Conjugate Development Solutions Business (2020-2025)

Figure 54. Revvity Revenue Growth Rate in Antibody–Drug Conjugate Development Solutions Business (2020-2025)

Figure 55. WuXi Biologics Revenue Growth Rate in Antibody–Drug Conjugate Development Solutions Business (2020-2025)

Figure 56. Abzena Revenue Growth Rate in Antibody–Drug Conjugate Development Solutions Business (2020-2025)

Figure 57. Samsung Biologics Revenue Growth Rate in Antibody–Drug Conjugate Development Solutions Business (2020-2025)

Figure 58. Bottom-up and Top-down Approaches for This Report

Figure 59. Data Triangulation

Figure 60. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic

$2900

Single User License

Multi User

Electronic

$4350

Multi User License

Enterprise License

Electronic

$5800

Enterprise License

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions